Biocept Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Biocept has been growing earnings at an average annual rate of 4.1%, while the Biotechs industry saw earnings growing at 17.4% annually. Revenues have been growing at an average rate of 34.9% per year.
Belangrijke informatie
4.1%
Groei van de winst
91.7%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | 34.9% |
Rendement op eigen vermogen | -10,554.1% |
Nettomarge | -2,255.5% |
Laatste winstupdate | 30 Jun 2023 |
Recente prestatie-updates uit het verleden
Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position
Nov 23Recent updates
Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth
Apr 17Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position
Nov 23Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings
Aug 19Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being
Jul 03Biocept and CLEARED4 ink collaboration agreement
Jun 09Biocept enters COVID-19 testing partnership
Apr 28Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain
Mar 13We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate
Jan 26Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?
Dec 22Biocept's assays viable and sensitive for detecting tumor cells and biomarkers
Nov 20Biocept +4% on COVID-19 testing update
Nov 12Opbrengsten en kosten
Hoe Biocept geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 23 | 1 | -31 | 15 | 4 |
31 Mar 23 | 7 | -37 | 17 | 5 |
31 Dec 22 | 26 | -32 | 23 | 6 |
30 Sep 22 | 41 | -25 | 25 | 6 |
30 Jun 22 | 57 | -16 | 27 | 6 |
31 Mar 22 | 63 | -8 | 26 | 6 |
31 Dec 21 | 61 | -3 | 21 | 5 |
30 Sep 21 | 66 | 2 | 21 | 5 |
30 Jun 21 | 55 | -2 | 20 | 4 |
31 Mar 21 | 44 | -7 | 18 | 5 |
31 Dec 20 | 27 | -18 | 16 | 5 |
30 Sep 20 | 11 | -25 | 14 | 5 |
30 Jun 20 | 6 | -26 | 13 | 5 |
31 Mar 20 | 6 | -28 | 13 | 5 |
31 Dec 19 | 6 | -25 | 13 | 5 |
30 Sep 19 | 5 | -26 | 13 | 5 |
30 Jun 19 | 4 | -27 | 13 | 5 |
31 Mar 19 | 3 | -25 | 12 | 5 |
31 Dec 18 | 3 | -25 | 13 | 4 |
30 Sep 18 | 3 | -25 | 13 | 4 |
30 Jun 18 | 4 | -24 | 14 | 4 |
31 Mar 18 | 4 | -24 | 14 | 4 |
31 Dec 17 | 5 | -22 | 14 | 3 |
30 Sep 17 | 5 | -20 | 13 | 3 |
30 Jun 17 | 5 | -19 | 13 | 3 |
31 Mar 17 | 5 | -18 | 12 | 3 |
31 Dec 16 | 3 | -18 | 12 | 3 |
30 Sep 16 | 2 | -19 | 11 | 3 |
30 Jun 16 | 1 | -19 | 11 | 3 |
31 Mar 16 | 1 | -18 | 10 | 3 |
31 Dec 15 | 1 | -17 | 10 | 3 |
30 Sep 15 | 0 | -16 | 9 | 3 |
30 Jun 15 | 0 | -16 | 8 | 4 |
31 Mar 15 | 0 | -15 | 7 | 4 |
31 Dec 14 | 0 | -16 | 7 | 4 |
30 Sep 14 | 0 | -14 | 6 | 4 |
30 Jun 14 | 0 | -13 | 5 | 4 |
31 Mar 14 | 0 | -12 | 4 | 3 |
31 Dec 13 | 0 | -9 | 3 | 3 |
30 Sep 13 | 0 | -10 | 2 | 4 |
30 Jun 13 | 0 | -10 | 2 | 4 |
31 Mar 13 | 0 | -11 | 3 | 5 |
31 Dec 12 | 0 | -12 | 3 | 7 |
Kwaliteitswinsten: BIOC is currently unprofitable.
Groeiende winstmarge: BIOC is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: BIOC is unprofitable, but has reduced losses over the past 5 years at a rate of 4.1% per year.
Versnelling van de groei: Unable to compare BIOC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: BIOC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Rendement op eigen vermogen
Hoge ROE: BIOC has a negative Return on Equity (-10554.14%), as it is currently unprofitable.